Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| COLL | PRESS-RELEASE | bullish | 7/10 | Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 mil | May 12, 2026 |
| HBIO | PRESS-RELEASE | neutral | 4/10 | Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.6% YoY from $21.8M, and a GAAP net loss of $(3.4)M, improv | May 12, 2026 |
| SABS | PRESS-RELEASE | bearish | 7/10 | SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9 | May 12, 2026 |
| MREO | PRESS-RELEASE | bearish | 6/10 | Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated | May 12, 2026 |
| XLO | PRESS-RELEASE | bullish | 7/10 | Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a year ago) and a net lo | May 12, 2026 |
| NYAX | PRESS-RELEASE | bullish | 7/10 | Nayax reported Q1 2026 revenue of $106.9M (+32% YoY) and GAAP EPS of $0.034, well above the $0.13 consensus on a non-GAA | May 12, 2026 |
| SGMT | PRESS-RELEASE | mixed | 6/10 | Sagimet Biosciences reported Q1 2026 EPS of -$0.33 (GAAP), beating consensus of -$0.35, with net loss narrowing to $10.7 | May 12, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showin | May 12, 2026 |
| HUBG | PRESS-RELEASE | bearish | 8/10 | Hub Group announced a delay in filing its Q1 2026 10-Q and a restatement of its 2024 and 2023 financial statements due t | May 12, 2026 |
| CIGI | PRESS-RELEASE | neutral | 4/10 | Colliers Engineering & Design (U.S. division) has agreed to partner with FSB, an Oklahoma City-based engineering firm sp | May 12, 2026 |
| UNCY | PRESS-RELEASE | bearish | 6/10 | Unicycive reported Q1 2026 EPS of -$0.54, significantly missing the consensus estimate of -$0.47, driven by a $4.8M non- | May 12, 2026 |
| NRXS | PRESS-RELEASE | bullish | 7/10 | NeurAxis reported Q1 2026 revenue of $1.6M (+80% YoY) and EPS of -$0.17, beating consensus estimates of $1.4M and -$0.19 | May 12, 2026 |
| ARVN | PRESS-RELEASE | bearish | 8/10 | Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing | May 12, 2026 |
| OVID | PRESS-RELEASE | mixed | 6/10 | Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a | May 12, 2026 |
| MWH | PRESS-RELEASE | bullish | 8/10 | SOLV Energy reported Q1 2026 revenue of $677M (up 66% YoY) and an adjusted EBITDA of $93M (up 174% YoY), significantly e | May 12, 2026 |
| TENX | PRESS-RELEASE | neutral | 5/10 | Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net loss widened to $15.7M | May 12, 2026 |
| ACHV | PRESS-RELEASE | mixed | 6/10 | Achieve Life Sciences reported Q1 2026 EPS of -$0.28, beating consensus of -$0.30 by 6.7%. The company also closed a $35 | May 12, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech reported Q1 2026 revenue of $305.1M (vs $306.5M consensus, slight miss) and EPS of -$0.15 (GAAP) vs conse | May 12, 2026 |
| SION | PRESS-RELEASE | neutral | 6/10 | Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16. | May 12, 2026 |
| IMTX | PRESS-RELEASE | mixed | 6/10 | Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21 | May 12, 2026 |
| IRD | PRESS-RELEASE | bearish | 7/10 | Opus Genetics reported Q1 2026 EPS of -$0.75, a 212.5% miss vs consensus of -$0.14, driven by a $51.4M non-cash fair val | May 12, 2026 |
| OLMA | PRESS-RELEASE | neutral | 5/10 | Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $ | May 12, 2026 |
| PRLD | PRESS-RELEASE | bullish | 7/10 | Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensu | May 12, 2026 |
| BWEN | PRESS-RELEASE | mixed | 5/10 | Broadwind reported Q1 2026 revenue of $34.1M (down 7.5% YoY) but beat consensus estimates on both revenue and EPS, with | May 12, 2026 |
| CCCC | PRESS-RELEASE | mixed | 5/10 | C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M | May 12, 2026 |
| CALM | PRESS-RELEASE | mixed | 5/10 | Cal-Maine Foods is acquiring the Van's Foods business (gluten-free frozen waffles/pancakes) from Sara Lee Frozen Bakery, | May 12, 2026 |
| ABOS | PRESS-RELEASE | neutral | 5/10 | Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi | May 12, 2026 |
| ETOR | PRESS-RELEASE | bullish | 8/10 | eToro reported Q1 2026 GAAP diluted EPS of $0.86 (vs consensus $0.70, beat by 22.9%) and total revenue of $2.44B. Net Co | May 12, 2026 |
| GNK | PRESS-RELEASE | mixed | 6/10 | Genco Shipping issued a press release rebutting Diana Shipping's hostile proxy campaign, highlighting Q1 2026 net income | May 12, 2026 |
| LAR | PRESS-RELEASE | bullish | 7/10 | Lithium Argentina reported Q1 2026 net income of $7.5M (EPS $0.05), swinging from a $7.2M loss in Q1 2025, driven by a $ | May 12, 2026 |